Gyroscope Therapeutics Holdings Ltimited (VISN)

Gyroscope Therapeutics Holdings Ltimited was planning to go public, but the IPO has been withdrawn.
IPO Price Range
$20.00 - $22.00
Shares Offered
6,750,000
Deal Size
$141.75M
Chart not available yet
Data will show when the stock starts trading.
Market Cap 613.82M
Revenue (ttm) 864,000
Net Income (ttm) -53.17M
Shares Out 29.23M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About VISN

Gyroscope Therapeutics is a global clinical-stage gene therapy company developing gene therapy beyond rare diseases. Our mission is to preserve sight and fight the devastating impact of blindness. Our science is grounded in the genetic understanding of patients with serious eye diseases to make medicines designed to have a meaningful impact. Our initial focus is age-related macular degeneration, or AMD, one of the leading causes of irreversible blindness, affecting more than 196 million people worldwide. We are developing a differentiated pipel... [Read more...]

Industry Biological Products
Founded 2016
CEO Khurem Farooq
Employees 167
Stock Exchange NASDAQ
Ticker Symbol VISN
Full Company Profile

Financial Performance

In 2020, VISN's revenue was $864,000, a decrease of -70.87% compared to the previous year's $2.97 million. Losses were -$53.17 million, 58.6% more than in 2020.

Financial Statements

News

Gyroscope Therapeutics Announces Research Collaboration Agreement with Children's Medical Research Institute to Devel...

LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics announces research collaboration agreement with Children's Medical Research Institute to develop novel gene therapy capsids.

1 year ago - Business Wire